Biological
VLA2001
VLA2001 is a biological therapy with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_1
1
20%
Ph phase_3
2
40%
Ph phase_2
2
40%
Phase Distribution
1
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 32 (40.0%)
Trials by Status
completed480%
withdrawn120%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_3
Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years
NCT04956224
completedphase_2
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
NCT05364242
completedphase_3
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
NCT04864561
withdrawnphase_2
COVID-19 Paediatric VLA2001-321 Study
NCT05298644
completedphase_1
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
NCT04671017
Clinical Trials (5)
Showing 5 of 5 trials
NCT04956224Phase 3
Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years
NCT05364242Phase 2
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
NCT04864561Phase 3
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
NCT05298644Phase 2
COVID-19 Paediatric VLA2001-321 Study
NCT04671017Phase 1
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5